CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 160 enrolled
Drug / intervention
Escitalopram +1 moredrug
Likely dose
Escitalopram 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00732901
NCT00732901Phase 3Completed
CompareCT.gov

Project 1: Clinical Neurobiology of Serotonin and Addiction

Virginia Commonwealth University·interventional·Posted Aug 12, 2008·Updated Mar 8, 2019

In Brief

A Phase 3 clinical trial evaluating Escitalopram and Placebo for Cocaine Dependence. Completed, enrolled 160 participants across 1 site.

Detailed Summary

The purpose of this study is to examine the relationship between 5-HT2R function, impulsivity and cue reactivity in cocaine dependent subjects and healthy controls and examine specific effects of escitalopram and mirtazapine on impulsivity and cue reactivity in human cocaine users.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCocaine Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA), The University of Texas Health Science Center, Houston

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 12, 2008
Enrollment StartJun 1, 2008
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 17.9 years ago

Interventions

Escitalopramdrug

Escitalopram: once daily 10 mg on days 1-3, 20 mg on days 4-24 and 10 mg on days 25-28

Placebodrug

Once daily days 1-28